Mind Medicine (MindMed) Inc. Common Shares (MNMD) Stock Price, Quote & AI Analysis

Live MNMD stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Mind Medicine (MindMed) Inc. Common Shares.

TradeVae provides AI-driven analysis and real-time market intelligence for Mind Medicine (MindMed) Inc. Common Shares (NASDAQ: MNMD), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

MNMD
Mind Medicine (MindMed) Inc. Common Shares
XNAS MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
real-time
$0.00 +0.00 (+0.00%)
Market Cap
$1,137,464,558.10
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Mar 4, 2026 Q4
After Hours
EPS Estimate: $-0.5109
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Mind Medicine (MindMed) Inc. Common Shares's fundamentals reflect its scale, profitability, and position within the global MEDICINAL CHEMICALS & BOTANICAL PRODUCTS sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Mind Medicine (MindMed) Inc. Common Shares Overview

Company information

Company Overview

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Company Details
Market Cap
$1.14B
Weighted Shares Outstanding
97,219,193
Address
ONE WORLD TRADE CENTER, NEW YORK, NY, 10007
Phone
212-220-6633
Employees
74
Industry
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Exchange
XNAS
Listed
Mar 2020

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Mind Medicine (MindMed) Inc. Common Shares Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...